RSV in Adults: Hospitalization, Long-Term Symptoms & Quality of Life

The narrative around respiratory illnesses has been dominated by COVID-19 for the past four years, but a growing body of evidence reveals that RSV – long considered a childhood concern – poses a significant and lasting health threat to adults, rivaling the long-term impacts of COVID-19 itself. New research from the University of Michigan reinforces this, demonstrating substantial and persistent impairments in physical function and quality of life months after RSV hospitalization, even in those under 60. This isn’t simply a more severe cold; it’s a disease capable of causing long-term disability and economic burden.

The Rising Threat of Adult RSV: A Contextual Deep Dive

For decades, RSV was primarily viewed as a pediatric illness, causing bronchiolitis and pneumonia in infants and young children. However, with an aging population and increased awareness, the burden of RSV in adults – particularly those over 60 – has become increasingly apparent. Prior to the recent development of RSV vaccines, the US saw an estimated 100,000 to 150,000 RSV hospitalizations annually among older adults, costing the healthcare system over $1.5 billion. The virus contributes substantially to hospital admissions for conditions like pneumonia, COPD, heart failure, and asthma exacerbations. The recent study, utilizing data from the SunRISE program (February 2022 – September 2023) and encompassing over 600 hospitalized RSV patients, provides crucial data on the *long-term* consequences, something previously lacking in the research.

The findings are particularly noteworthy because they demonstrate that the post-acute sequelae of RSV are not negligible. The observed impairments in physical function and quality of life are comparable in scope to those seen after COVID-19 hospitalization, and dyspnea (shortness of breath) was, in fact, *more* severe in the RSV cohort. This suggests that RSV deserves a level of attention and preventative measures previously reserved for COVID-19.

The Forward Look: What Happens Next?

The recent approval of the first RSV vaccines for older adults (from Pfizer and GSK) represents a critical step forward in mitigating the impact of this disease. However, the study’s findings underscore the need for a multi-pronged approach. We can expect to see increased public health campaigns promoting RSV vaccination, particularly among those over 60, and potentially expanding recommendations to younger at-risk populations.

More importantly, this research will likely drive a shift in how healthcare systems prepare for and manage RSV outbreaks. The comparable long-term effects to COVID-19 suggest a need for dedicated post-discharge care pathways for RSV patients, including pulmonary rehabilitation and mental health support. Further research is needed to understand the underlying mechanisms driving these long-term impairments and to identify potential therapeutic interventions. Finally, expect increased scrutiny on RSV surveillance data to better track the virus’s prevalence and impact, informing future vaccine strategies and public health policies. The focus is shifting from simply preventing acute infection to minimizing the potential for long-term disability – a paradigm shift that will reshape our approach to respiratory illness management.

REFERENCES

1.Leis AM, Womack KN, Maxcy C, et al. Long-Term Illness in Adults Hospitalized for Respiratory Syncytial Virus Disease, United States, February 2022–September 2023. Emerging Infectious Diseases. 2026;32(13). doi:10.3201/eid3213.241982

2. Study: Adults face lasting effects months after RSV hospitalization. News release. EurekAlert! December 10, 2025. Accessed December 23, 2025. https://www.eurekalert.org/news-releases/1109358